Heparin-induced thrombocytopenia after implantation of a heparin-bonded polytetrafluoroethylene lower extremity bypass graft: A case report and plan for management.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19341891.
- Also identified by DOI 10.1016/j.jvs.2008.12.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The proprietary heparin-bonded expanded polytetrafluoroethylene graft appears to be an attractive option for lower extremity revascularization in patients with compromised runoff and no autogenous vein. There is no detectable elution of heparin from the graft surface, but antithrombotic activity has been detected in devices implanted for >2 years. Although 15,000 Propaten (W. L. Gore and Associates, Flagstaff, Ariz) grafts have been implanted, to our knowledge, this is the first report of heparin-induced thrombocytopenia developing from this heparin-bonded graft. The heparin-induced thrombocytopenia responded promptly to graft explantation. A management plan is suggested for patients being considered for this graft.
Medical subject headings
- Anticoagulants
- Blood Vessel Prosthesis
- Blood Vessel Prosthesis Implantation
- Coated Materials, Biocompatible
- Heparin
- Lower Extremity
- Peripheral Vascular Diseases
- Polytetrafluoroethylene
- Thrombocytopenia